This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Antimetabolite Drugs Market

Market Insights on Antimetabolite Drugs market covering sales outlook, demand forecast & up-to-date key trends

Antimetabolite Drugs Market by Drug Class, Route of Administration, Application, Distribution Channel & Region - Forecast 2022 - 2032

Antimetabolite Drugs Market Overview

Expanding at a CAGR of 1.8%, the global Antimetabolite Drugs market is projected to increase from a valuation of US$ 5,504.3 Mn in 2021 to US$ 6,579.2 Mn by 2032.

“Upsurge in the usage of Antimetabolite Drugss in the cancer therapies and increasing healthcare expenditure will help the global Antimetabolite Drugs market to generate great revenue in the projected period.”

Attributes

Details

Antimetabolite Drugs Market Value in 2021

US$ 5,504.3 Mn

Antimetabolite Drugs Market Value in 2032

US$ 6,579.2 Mn

Antimetabolite Drugs Market CAGR (2022-2032)

1.8%

Drugs that interfere with enzymes and their reactions that are necessary for DNA synthesis are known as antimetabolites. S-Phase is used to build new DNA molecules, antimetabolite interferes and slows the synthesis of pyrimidine and purine which induce the death of cells. Antimetabolites are useful in cancer treatment but are toxic to the normal cell.

Antimetabolites are folic acids and pyrimidine or purine equivalents. These molecules are one of the crucial chemotherapeutic agents and are characterized by low molecular weight molecules. As these compounds have a similar structure to molecules used in nucleic acid synthesis, these molecules are used for different cancer treatments, which include pancreatic cancer, breast cancer, leukaemia, gastro-intestinal cancer, and ovarian cancer.

The existence of Antimetabolite Drugs has a false impact on cell cycles as these drugs inhibit cell division and growth. Therefore, these drugs are commonly used as chemotherapeutics in various cancer cases. Besides cancer therapeutics, Antimetabolite Drugs have different applications such as antibiotics and trabeculectomy.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Factors Responsible for the Growth of the Antimetabolite Drugs Market?

The rapid development in the fields of oncology and drug delivery is expected to show significant growth in the Antimetabolite Drugs market during the forecast period. Additionally, the increased government investments in cancer treatment and diagnosis, research, and initiative to create awareness about cancer are anticipated to drive the global Antimetabolite Drugs market growth.

Moreover, an increase in unhealthy habits such as smoking, and consumption of tobacco are common factors that can cause cancer. This, in turn, is projected to propel the growth of the Antimetabolite Drugs market. Furthermore, an increase in the spending on research and development for cancer research activities in biotechnology and pharmaceutical firms is expected to boost market growth.

Which Region Shows Strong Growth Potential in the Antimetabolite Drugs Market?

Due to well-established research infrastructure and rising interest in research activities, North America dominated the Antimetabolite Drugs market and is expected to show the same growth in the forecast period. Owing to the increasing research on cancer therapeutic and government supported funding policies, Europe has shown high growth in the Antimetabolite Drugs market.

Followed by Europe, East Asia and South Asia is expected to show the rapid growth over the forecast period. This is due to the increased prevalence of cancer and the focus of the government on the development of the medical infrastructure.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Who are the Key Manufacturers of the Antimetabolite Drugs Market?

Some of the key players operating in the Antimetabolite Drugs market are Parenteral Drugs Limited., Bristol-Myers Squibb Company, Merck & Co., Inc., Fresenius Kabi Oncology Limited, GlaxoSmithKline plc, Cadila Pharmaceuticals., CELON LABS, Sanofi, Eli Lilly and Company (Lilly), Novartis AG, and Teva Pharmaceutical Industries Ltd.

Scope of the Report

Attributes

Details

Forecast Period

2022-2032

Historical Data Available for

2012-2021

Market Analysis

US$ Mn for Value

By Drug Class

  • Pyrimidine Compounds
  • Purine Compounds
  • Folate Antagonists
  • Demethylation Agents

By Route of Administration

  • Oral
  • Intravenous
  • Intramuscular

By Application

  • Cancer Therapeutic
  • Cardiac Therapeutic
  • Arthritis Therapeutic

By Distribution Channel

  • Retail Sales
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Players

  • Parenteral Drugs Limited.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Fresenius Kabi Oncology Limited
  • GlaxoSmithKline plc
  • Cadila Pharmaceuticals
  • CELON LABS
  • Sanofi SA
  • Eli Lilly and Company (Lilly)
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Key Segments Covered in the Antimetabolite Drug Industry Survey

By Drug Class:

  • Pyrimidine Compounds
  • Purine Compounds
  • Folate Antagonists
  • Demethylation Agents

By Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular

By Application:

  • Cancer Therapeutic
  • Cardiac Therapeutic
  • Arthritis Therapeutic

By Distribution Channel:

  • Retail Sales
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

The global Antimetabolite Drugs market is anticipated to register a CAGR of 1.8% during the forecast period.

The top 3 players in the global Antimetabolite Drugs market are Parenteral Drugs Limited., Bristol-Myers Squibb Company, and Merck & Co.

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Antimetabolite Drugs Market